Proof of principle data from Phase I part of the Phase I/II trial of TG4050 in the adjuvant setting of head and neck cancer. All TG4050-treated patients remained disease-free after median follow-up of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback